Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy January 26, ...

After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.

YUEQING, ZHEJIANG, CHINA, January 23, 2026 /EINPresswire.com/ — WENZHOU, CHINA — As we move into 2026, the global industrial landscape is witnessing a profound shift toward intelligent manufacturing, ...

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today announced positive topline three-year functional results from Part 1-treated patients in EMBARK (Study ...

Car manufacturers are trialing spider-silk bioleather in seats and interior components, probing the hard limits of automotive-grade performance.

Mike Pelayo defines himself as a builder at heart—one who has worked across construction, food, sports, and agriculture. From growing a chicken barbecue brand—Vito’s Barbecue—to helping develop boxing ...

As the new robot called Sprout walks around a Manhattan office, nodding its rectangular head, lifting its windshield ...

Raphael Gomes tests a 3-second watermelon slicer to see if it really works. America’s ‘Achilles heel’ of national debt is exposed by Trump’s Greenland tariff threat, warns Deutsche Bank Mendoza, a ...

The initial hype and the vast sums of money thrown at the sector have dissipated but that’s not to say the long-term ...

Oregon Coordinated Care Organization to Leverage 1upHealth's Comprehensive Interoperability Suite to Drive CMS ...

BMW iX1 Long Wheelbase electric SUV launched at Auto Expo 2025. Check price range, battery, features ...